Treatment of Acutely Decompensated Heart Failure

Management of Heart Failure

Volumn , Issue , 2010, Pages 327-356

  Teerlink, John R ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute Decompensated Heart Failure National Registry (ADHERE) industry sponsored, large, national (USA); Acute heart failure (AHF), relatively ignored compared to chronic or congestive heart failure (CHF); Acute heart failure pathophysiology; Acute heart failure, based on specific clinical characteristics presented by European Society of Cardiology heart failure guidelines; AHF, and pathophysiological abnormality with identifiable trigger or precipitating event; Dyspnea, most common symptom in patients with AHF; Phosphodiesterase inhibitors (PDEI) and cAMP, a ubiquitous signaling molecule increasing inotropy; Pre discharge phase focusing on goals of optimizing chronic oral therapy; Pulmonary artery catheter (PAC) important diagnostic tool in selected patients; Treatment of acutely decompensated heart failure

Indexed keywords

EID: 84886154073     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470669402.ch14     Document Type: Chapter

References (89)

1. Teerlink JR. Diagnosis and Management of Acute Heart Failure. In: Libby P, Bonow RO, Mann DM, Zipes DP, eds. Braunwald's Heart Disease. 8th ed. Philadelphia: Elsevier; 2008:583-610.
2. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol, 2009; 53: 557-573.
3. Mebazaa A, Gheorghiade M, Zannad F, E PJ, eds. Acute heart failure. London: Springer-Verlag; 2008.
4. O'Connor CM, Stough WG, Gheorghiade M, Adams KF, eds. Managing Acute Decompensated Heart Failure: A Clinician's Guide for Diagnosis and Treatment. London: Taylor and Francis, LTD; 2005.
5. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009. 119:e21-181.
6. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 2005; 26: 1115-1140.
7. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J, 2008; 29: 2388-2442.
8. Nieminen MS, Bohm M, Cowie MR et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J, 2005; 26: 384-416.
9. Nohria A, Tsang SW, Fang JC et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. JAm Coll Cardiol, 2003; 41: 1797-1804.
10. Hunt SA, Abraham WT, Chin MH et al.2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. JAm Coll Cardiol, 2009;53:e1-e90.
11. Galvao M, Kalman J, DeMarco T et al. Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Card Fail, 2006; 12: 100-107.
12. Nieminen MS, Brutsaert D, Dickstein K et al. Euro-Heart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J, 2006; 27: 2725-2736.
13. Rudiger A, Harjola VP, Muller A et al. Acute heart failure: clinical presentation, one-year mortality and prognostic factors. Eur J Heart Fail, 2005; 7: 662-670.
14. Tavazzi L, Maggioni AP, Lucci D et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J, 2006; 27: 1207-1215.
15. ADHERE Scientific Advisory Committee. Acute Decompensated Heart Failure National Registry (ADHERE® ) Core Module Q1 2006 Final Cumulative National Benchmark Report: Scios, Inc.; 2006.
16. Rathore SS, Foody JM, Wang Y et al. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. Jama, 2003; 289: 2517-2524.
17. Yancy C, Stough WG, Abraham WT, Greenberg B, She L, Fonarow GC. Defining the natural history and improving quality of care for African-Americans hospitalized with heart failure: A report from OPTIMIZE-HF. J Card Fail 2005. 11:S190.
18. Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J, 2003; 24: 442-463.
19. Felker GM, Leimberger JD, Califf RM et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail, 2004; 10: 460-466.
20. Gheorghiade M, Abraham WT, Albert NM et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. Jama, 2006; 296: 2217-2226.
21. Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med, 2002; 162: 1689-1694.
22. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. Jama, 2003; 290: 2581-2587.
23. O'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail, 2005; 11: 200-205.
24. Zannad F, Mebazaa A, Juilliere Y, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail, 2006; 8: 697-705.
25. Gheorghiade M, Zannad F, Sopko G et al. Acute heart failure syndromes: current state and framework for future research. Circulation, 2005; 112: 3958-3968.
26. Fonarow GC, Adams KF, Jr., Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. Jama 2005. 293:572-580.
27. Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. Jama 2003. 289:194-202.
28. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med, 2004; 350: 1953-1959.
29. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail, 2007; 13: 422-430.
30. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol, 2009; 53: 582-588.
31. Mullens W, Abrahams Z, Francis GS et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol, 2009; 53: 589-596.
32. Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med, 2005; 353: 2788-2796.
33. Peacock WFt, DeMarco T, Fonarow GC et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med, 2008; 358: 2117-2126.
34. Aronson D, Burger AJ. Neurohormonal prediction of mortality following admission for decompensated heart failure. Am J Cardiol, 2003; 91: 245-248.
35. Perna ER, Barbagelata A, Grinfeld L et al. Overview of acute decompensated heart failure in Argentina: lessons learned from 5 registries during the last decade. Am Heart J, 2006; 151: 84-91.
36. Heart Failure Society of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail 2006. 12:e86-e103.
37. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med, 2002; 347: 161-167.
38. Januzzi JL, van Kimmenade R, Lainchbury J et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J, 2006; 27: 330-337.
39. Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med, 2004; 350: 647-654.
40. Metra M, Nodari S, Parrinello G et al. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail, 2007; 9: 776-786.
41. Gandhi SK, Powers JC, Nomeir AM et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med, 2001; 344: 17-22.
42. Shah MR, Hasselblad V, Stevenson LW et al. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. Jama, 2005; 294: 1664-1670.
43. Binanay C, Califf RM, Hasselblad V et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. Jama, 2005; 294: 1625-1633.
44. Teerlink JR. Overview of randomized clinical trials in acute heart failure syndromes. Am J Cardiol 2005. 96:59G-67G.
45. Gray AJ, Goodacre S, Newby DE et al. A multicentre randomised controlled trial of the use of continuous positive airway pressure and non-invasive positive pressure ventilation in the early treatment of patients presenting to the emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO trial. Health Technol Assess, 2009; 13: 1-106.
46. Aronson D, Burger AJ. Concomitant beta-blocker therapy is associated with a lower occurrence of ventricular arrhythmias in patients with decompensated heart failure. J Card Fail, 2002; 8: 79-85.
47. Butler J, Young JB, Abraham WT et al. Betablocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol, 2006; 47: 2462-2469.
48. Cotter G, Metzkor E, Kaluski E et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet, 1998; 351: 389-393.
49. VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. Jama, 2002; 287: 1531-1540.
50. Elkayam U, Akhter MW, Singh H, Khan S, Usman A. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol, 2004; 93: 237-240.
51. Johnson W, Omland T, Hall C et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol, 2002; 39: 1623-1629.
52. Durrer JD, Lie KI, van Capelle FJ, Durrer D. Effect of sodium nitroprusside on mortality in acute myocardial infarction. N Engl J Med, 1982; 306: 1121-1128.
53. Cohn JN, Franciosa JA, Francis GS et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med, 1982; 306: 1129-1135.
54. Mullens W, Abrahams Z, Francis GS et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol, 2008; 52: 200-207.
55. Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. Jama, 2006; 296: 1465-1466.
56. Sackner-Bernstein JD, Kowalski M, Fox M, Aaron-son K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. Jama, 2005; 293: 1900-1905.
57. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation, 2005; 111: 1487-1491.
58. Teerlink JR, Massie BM. Nesiritide and worsening of renal function: the emperor's new clothes? Circulation, 2005; 111: 1459-1461.
59. Coletta AP, Cleland JG, Freemantle N, Clark AL. Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail, 2004; 6: 673-676.
60. Follath F, Cleland JG, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet, 2002; 360: 196-202.
61. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med, 2005; 142: 510-524.
62. Metra M, Nodari S, D'Aloia A et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol, 2002; 40: 1248-1258.
63. Cuffe MS, Califf RM, Adams KF, Jr. et al. Shortterm intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. Jama, 2002; 287: 1541-1547.
64. Felker GM, Benza RL, Chandler AB et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol, 2003; 41: 997-1003.
65. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail, 2006; 8: 105-110.
66. Costanzo MR, Guglin ME, Saltzberg MT et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol, 2007; 49: 675-683.
67. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005. 46:e1-82.
68. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol, 2004; 43: 1534-1541.
69. Fonarow GC, Abraham WT, Albert NM et al. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: An analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2007;153: 82 e81-82 e11.
70. Phillips CO, Wright SM, Kern DE, Singa RM, Shep-perd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. Jama, 2004; 291: 1358-1367.
71. deGoma EM, Vagelos RH, Fowler MB, Ashley EA. Emerging therapies for the management of decompensated heart failure: from bench to bedside. J Am Coll Cardiol, 2006; 48: 2397-2409.
72. Ghali JK, Smith WB, Torre-Amione G et al. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. Am J Cardiol 2007. 99:47A-56A.
73. Gheorghiade M, Blair JE, Filippatos GS et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. JAm Coll Cardiol, 2008; 51: 2276-2285.
74. Teerlink JR, Malik FI, Clarke CP et al. The selective cardiac myosin activator, CK-1827452, increases left ventricular systolic function by increasing ejection time: Results of a first-in-human study of a unique and novel mechanism. J Card Fail 2006. 12:763.
75. Teerlink JR. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev 2009.
76. Mitrovic V, Luss H, Nitsche K, et al. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J 2005. 150:1239.e1231-1239.e1238.
77. Mitrovic V, Seferovic PM, Simeunovic D et al. Haemo-dynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J, 2006; 27: 2823-2832.
78. Chen HH, Martin FL, Cataliotti A, Schirger JA, Burnett JC. AlbuBNP (Cardeva), a Novel Recombinant Human B-Type Natriuretic Peptide Serum Albumin Fusion Protein Has Prolonged Renal Enhancing Properties When Compared to Human BNP. Journal of Cardiac Failure 2007. 13:S145.
79. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC, Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol, 2008; 52: 60-68.
80. Dschietzig T, Bartsch C, Baumann G, Stangl K. Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacology & Therapeutics, 2006; 112: 38-56.
81. Teerlink JR, Metra M, Felker GM et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet, 2009; 373: 1429-1439.
82. Gottlieb SS, Brater DC, Thomas I et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation, 2002; 105: 1348-1353.
83. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC. The Effects of KW-3902, an Adenosine A1-Receptor Antagonist,on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure and Renal Impairment or Diuretic Resistance. Journal of the American College of Cardiology, 2007; 50: 1551-1560.
84. Cotter G, Dittrich HC, Weatherley BD et al. The PROTECT pilot study: a randomized, placebocontrolled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008. 14:631-640.
85. Ho JE, Teerlink JR. Role of tolvaptan in acute decompensated heart failure. Expert Rev Cardiovasc Ther, 2008; 6: 601-608.
86. Gheorghiade M, Konstam MA, Burnett JC, Jr. et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. Jama, 2007; 297: 1332-1343.
87. Konstam MA, Gheorghiade M, Burnett JC, Jr. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. Jama, 2007; 297: 1319-1331.
88. Pang PS, Konstam MA, Krasa HB et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 2009.
89. McMurray JJ, Teerlink JR, Cotter G et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. Jama, 2007; 298: 2009-2019.